For the full clinical evidence on DoxyPEP — the trials, the dosing protocol, who it's appropriate for, and the AMR debate — see DoxyPEP: The Evidence & The Protocol first.

Switzerland's position on DoxyPEP is more advanced than most of its European neighbours. While official federal guidelines had not as of early 2026 formally endorsed DoxyPEP as standard care, the Checkpoint Zürich and the Swiss clinical infectious disease community have been among the earliest in Continental Europe to engage seriously with the evidence — and off-label prescribing is available through the right channels.

The Swiss Context

Switzerland's Checkpoint network, particularly Checkpoint Zürich, was among the first community sexual health services in Continental Europe to discuss DoxyPEP proactively with patients and to facilitate off-label prescribing through affiliated clinicians. This aligns with Switzerland's broader tradition of evidence-led harm reduction and a clinical culture that is comfortable with off-label prescribing when the evidence base is robust.

The Swiss HIV Cohort Study (SHCS), which is one of the most rigorous HIV cohort programmes in the world and which underpins SwissPrEPared, has also engaged with the DoxyPEP evidence. Researchers affiliated with the SHCS have been involved in the European debate.

The BAG (Federal Office of Public Health) had not issued a national DoxyPEP recommendation as of early 2026 — the formal guideline process takes time. But the clinical practice in Swiss Checkpoints and university hospital infectious disease departments is ahead of formal policy.

Practical Access

Via Checkpoint

Checkpoint Zürich is the most accessible route. At a monitoring appointment or a dedicated consultation, ask explicitly:

"Ich habe von Doxycyclin als PEP gegen Geschlechtskrankheiten gelesen. Können wir das besprechen?" (I've read about doxycycline as PEP against STIs. Can we discuss that?)

The medical staff at Checkpoint Zürich are familiar with the literature and can prescribe doxycycline off-label or facilitate a referral to an affiliated infectious disease physician who can.

Checkpoint Genève / Dialogai — similarly engaged, though Geneva's clinical culture moves at its own pace. Ask in the same way.

Via Infectious Disease Specialist

The infectious disease outpatient clinics at USZ (Zürich) and HUG (Geneva) include clinicians familiar with DoxyPEP evidence who are comfortable with off-label prescribing conversations. This is particularly applicable if you are already a patient there for PrEP monitoring.

Cost and Insurance

Doxycycline itself is a cheap drug — when prescribed off-label as DoxyPEP, the medication cost is modest (approximately 10–20 CHF per month at typical usage rates). The consultation to obtain the prescription is what varies. At a Checkpoint (cash), the consultation cost is absorbed into your regular visit fee. At a GP or hospital outpatient, it goes through the normal insurance/franchise route.

The AMR Dimension in Switzerland

Unlike Denmark, Switzerland is not leading Europe's antimicrobial resistance stewardship debate on this issue — the AMR concern is present but has not been the dominant reason for Swiss caution. The more relevant Swiss dynamic has been the gap between clinical practice (moving ahead) and formal guideline issuance (slow by design).

Switzerland's drug-resistant gonorrhoea rates are monitored by the BAG; the Checkpoint network contributes data. The emerging European consensus is that targeted DoxyPEP in high-incidence populations reduces syphilis and chlamydia significantly without, so far, demonstrating large resistance shifts in gonorrhoea — but the monitoring continues.

What to Discuss With Your Clinician

  • Be specific about your STI history and testing frequency — repeated STIs in the past year is a strong indicator for DoxyPEP
  • Ask whether this can be prescribed off-label and what the monitoring framework would look like
  • Clarify the dosing protocol: 200mg doxycycline within 72 hours of sex (not more frequently than every 24 hours)
  • Discuss whether it changes your current testing schedule — it generally doesn't; quarterly testing remains the recommendation regardless of DoxyPEP use

Related: